Skip to main content
Basilea Pharmaceutica AG logo

Basilea Pharmaceutica AG — Investor Relations & Filings

Ticker · BSLN ISIN · CH0011432447 LEI · 391200TTZP8EIPSJ5J20 SW Manufacturing
Open in API
Filings indexed 55 across all filing types
Latest filing 2026-04-09 Capital/Financing Update
Country CH Switzerland
Listing SW BSLN

About Basilea Pharmaceutica AG

https://www.basilea.com/

Basilea Pharmaceutica is a commercial-stage biopharmaceutical company that develops and commercializes innovative pharmaceutical products. The company focuses on meeting the medical needs of patients with severe and life-threatening conditions, particularly bacterial and fungal infections. Its core activities revolve around its key anti-infective products, Cresemba and Zevtera, with a strategy to establish them as global brands. Basilea has a proven track record of advancing drugs from research and development through to market commercialization, aiming to become a leading company in the anti-infectives field.

Recent filings

Filing Released Lang Actions
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
Capital/Financing Update Classification · 1% confidence The document is an ad hoc exchange announcement from Basilea Pharmaceutica Ltd reporting receipt of an additional USD 6 million in non-dilutive funding to support its antibiotic BAL2420 clinical study. It does not contain quarterly or annual financial statements, nor is it a governance, legal, or dividend notice. Instead, it specifically details a financing event (additional funding awarded). Therefore, it falls under the Capital/Financing Update category.
2026-04-09 English
Basilea erhält zusätzliche USD 6 Mio. von CARB-X für die klinische Entwicklung des Antibiotikums BAL2420
Capital/Financing Update Classification · 1% confidence The document is an ad hoc disclosure (“Ad hoc-Mitteilung gemäss Art. 53 KR”) by a Swiss-listed biopharma company announcing additional USD 6 million non-dilutive funding from CARB-X for its first-in-human clinical trial. It’s not an earnings release or annual/interim financial report, nor a management change, voting results, or delisting. It clearly constitutes a financing/capital update regarding grant funding for research activities. Therefore, it fits the Capital/Financing Update category (CAP).
2026-04-09 German
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance
Earnings Release Classification · 1% confidence The document is an 'Ad hoc announcement' detailing the financial results for the year ended December 31, 2025. It provides key financial highlights, management commentary, and future guidance. Crucially, it explicitly states that the full consolidated financial statements are available on the company's website, indicating this document is a summary release rather than the full 10-K report itself. Therefore, it is classified as an Earnings Release (ER). FY 2025
2026-02-17 English
Basilea erzielt starke Ergebnisse im Geschäftsjahr 2025 und übertrifft Umsatz- und Betriebsgewinn-Guidance
Earnings Release Classification · 1% confidence The document is an 'Ad hoc-Mitteilung' (Ad hoc announcement) from Basilea Pharmaceutica AG detailing their annual financial results for the fiscal year ending December 31, 2025. It includes key financial highlights, a summary of performance, a financial outlook (guidance) for 2026, and information regarding board of director nominations. While it contains financial data, it is an initial announcement of results rather than the full Annual Report (10-K) itself, as evidenced by the length and the explicit statement that the full consolidated financial report is available on their website. Therefore, it is classified as an Earnings Release. FY 2025
2026-02-17 German
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
Earnings Release Classification · 1% confidence The document is an ad hoc announcement regarding a USD 30 million sales milestone payment for the drug Cresemba. It is a short corporate announcement (under 5,000 characters) that provides information about a specific business event and includes a link to download the full press release as an attachment. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA). H1 2025
2025-11-04 English
Starke Verkaufszahlen für Cresemba® (Isavuconazol) in Europa lösen USD 30 Mio. Meilensteinzahlung an Basilea aus
Earnings Release Classification · 1% confidence The document is an 'Ad hoc-Mitteilung' (Ad hoc announcement) from Basilea Pharmaceutica AG regarding a milestone payment received from a licensing partner. It provides financial highlights (a $30 million milestone payment) and business updates. While it contains financial information, it is a corporate announcement rather than a full financial report or earnings release. According to the 'Menu vs Meal' rule, since it is a short announcement and includes a link to the full press release in the appendix, it is classified as a Regulatory Filing (RNS), which serves as the fallback for general corporate announcements. H1 2025
2025-11-04 German

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.